Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).

@article{Chang2014Phase2S,
  title={Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).},
  author={Julie Elizabeth Chang and Hailun Li and Mitchell R. Smith and Randy D. Gascoyne and Elisabeth Paietta and David T Yang and Ranjana Hira Advani and Sandra J. Horning and Brad S Kahl},
  journal={Blood},
  year={2014},
  volume={123 11},
  pages={1665-73}
}
Rituximab, bortezomib, modified hyper-cyclophosphamide, doxorubicin, vincristine, dexamethasone (VcR-CVAD) induction chemoimmunotherapy and maintenance rituximab (MR) were evaluated for efficacy and safety in Eastern Cooperative Oncology Group protocol E1405. Patients with previously untreated mantle cell lymphoma received VcR-CVAD chemotherapy every 21 days for 6 cycles, followed by MR for 2 years. Transplant-eligible patients had the option of autologous stem cell transplantation (ASCT… CONTINUE READING

11 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Rituximab , bortezomib , modified hyper - cyclophosphamide , doxorubicin , vincristine , dexamethasone ( VcR - CVAD ) induction chemoimmunotherapy and maintenance rituximab ( MR ) were evaluated for efficacy and safety in Eastern Cooperative Oncology Group protocol E1405 .
Rituximab , bortezomib , modified hyper - cyclophosphamide , doxorubicin , vincristine , dexamethasone ( VcR - CVAD ) induction chemoimmunotherapy and maintenance rituximab ( MR ) were evaluated for efficacy and safety in Eastern Cooperative Oncology Group protocol E1405 .
Rituximab , bortezomib , modified hyper - cyclophosphamide , doxorubicin , vincristine , dexamethasone ( VcR - CVAD ) induction chemoimmunotherapy and maintenance rituximab ( MR ) were evaluated for efficacy and safety in Eastern Cooperative Oncology Group protocol E1405 .
Rituximab , bortezomib , modified hyper - cyclophosphamide , doxorubicin , vincristine , dexamethasone ( VcR - CVAD ) induction chemoimmunotherapy and maintenance rituximab ( MR ) were evaluated for efficacy and safety in Eastern Cooperative Oncology Group protocol E1405 .
All Topics